ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

$ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma$

Updates in CLL - 2023 Best of Hematology ConferenceПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Multiple myeloma highlights from ASH 2020Подробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Relapsed Therapy and Clinical Trials - Dr. Caitlin Costello: RCW San Diego 2021Подробнее

Daratumumab + Pomalidomide & Dexamethasone Effective in Relapsed/Refractory Multiple MyelomaПодробнее

$Daratumumab + Pomalidomide & Dexamethasone Effective in Relapsed/Refractory Multiple Myeloma$

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

Clinical activity and safety of cevostamab in relapsed/refractory multiple myelomaПодробнее

$Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma$

What is isatuximab? And how does it compare with daratumumab?Подробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее